Why Minnesota Companies Are Looking Down Under

Local innovators like Imricor Medical Systems (ASX:IMR)  and Saluda Medical (ASX:SLD), Anteris Technologies (ASX:AVR)  have already tapped into the Australian market to fund their next phases of growth. Australia offers a deep pool of healthcare-focused institutional capital (backed by a $3.5T+ superannuation system) tailored for early-to-mid commercialization stage companies.

What You'll Gain:

• The "NASDAQ Gap" Solution: How the ASX provides public market liquidity without the massive market-cap demands and compliance overhead of U.S. exchanges.
• Investor & Valuation Dynamics: What Australian investors look for in U.S. healthcare and biotech platforms.
• A Firsthand Case Study: Hear directly from Steve Wedan, President & CEO of Imricor Medical Systems, as he shares Imricor’s experience accessing the Australian public markets, raising growth capital, and operating as an ASX-listed U.S. medtech company.
• Strategic Value for Investors: How VCs, PE funds, and advisors can leverage the ASX as a viable liquidity or follow-on financing pathway for portfolio companies.

Who Should Attend: Founders, CEOs, CFOs, healthcare investors (VC/PE), and strategic board advisors. 

Note: Companies do not need to be actively preparing for an IPO or currently operating in Australia to attend. This is an educational & informative executive session. 

Panelists:

Agenda:

8 :00 AM: Registration Opens. Networking with coffee and pastry.  

8.30 AM: Program Starts

• Introduction from Anette Lillegard, VP Partnerships, The Medical Alley Association 
• Australian Securities Exchange (ASX) Presentation 
  • Australia as a capital raising destination: Why Australia?
    • An overview of the ASX, IPO activity, capital raised & Healthcare / Life Sciences sector profile  
• JWS / GT Presentation 
  • ASX listing requirements and IPO process
  • ASX vs Nasdaq: key differences
  • Key considerations for prospective issuers
• Case Study: The ASX experience, [ASX listed US issuer representative] [20 mins] 
• Open discussion and Q&A